Bellcross Cecelia, Dotson W David
National Office of Public Health Genomics, CDC.
PLoS Curr. 2010 Sep 2;2:RRN1178. doi: 10.1371/currents.RRN1178.
Differences in the expression of specific genes within breast tumors have been associated with risk of recurrence after treatment. Most women with Stage I or II node-negative breast cancer (especially when estrogen-receptor positive and treated with tamoxifen) remain disease-free at 10 years. Information on risk of recurrence could help identify women most likely to benefit from chemotherapy. Several clinically available gene expression profiles (GEP) provide "recurrence risk scores" that are intended to supplement information used by clinicians and patients in treatment decision-making.
乳腺肿瘤内特定基因表达的差异与治疗后复发风险相关。大多数I期或II期淋巴结阴性乳腺癌女性（尤其是雌激素受体阳性且接受他莫昔芬治疗者）10年后仍无疾病复发。复发风险信息有助于识别最可能从化疗中获益的女性。几种临床可用的基因表达谱（GEP）提供“复发风险评分”，旨在补充临床医生和患者在治疗决策中使用的信息。
